{"transactions":[{"id":4640544,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":184442,"kind":"person","name":"Vat-Ho Vatnak","position":1,"cik":"0002160022","reported_name":"Vat-Ho Vatnak","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-14T21:21:58.000Z","date":"2026-10-12","kind":"grant","planned":false,"acquired":true,"shares":87000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 5, 2026 (the \"Grant Date\"), the reporting person was granted an option to purchase 87,000 ADSs. This option grant is subject to forfeiture and cancellation if shareholder approval of a proposed amendment to the Issuer's equity incentive plan to increase the number of shares reserved for issuance under the plan is not obtained. The option will vest with respect to 25% on the 12-month anniversary of the Grant Date, with the remainder vesting in equal monthly installments over the next 36 months until fully vested on the 4-year anniversary of the Grant Date, subject to the grantee's continued service with the Company."}],"balance_after":87000,"derivative":{"exercise_price":8.94,"expiration_date":"2036-10-05","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":87000},"source":{"system":"sec-edgar","filing":"0001493152-26-047058","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2160022/000149315226047058/ownership.xml","form_type":"4"}},{"id":4634132,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":35441,"kind":"person","name":"Gaslightwala Abizer","position":1,"cik":"0002049375","reported_name":"Gaslightwala Abizer","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2026-10-02T00:50:22.000Z","date":"2026-09-29","kind":"grant","planned":false,"acquired":true,"shares":6430,"price":9.72,"value":62499.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These American Depositary Shares represent restricted stock units (\"RSUs\"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. RSUs were granted on September 29, 2026 and vest in four approximately equal quarterly installments on November 18, 2026, February 18, 2027, May 18, 2027, and August 18, 2027, subject to continued service. The RSUs are subject to forfeiture and cancellation if the Issuer's shareholders do not approve an amendment to the Issuer's equity incentive plan increasing the number of shares reserved for issuance under the plan."}],"balance_after":14107,"source":{"system":"sec-edgar","filing":"0001493152-26-045366","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2049375/000149315226045366/ownership.xml","form_type":"4"}},{"id":681809,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":21766,"kind":"person","name":"Farag Kameel D.","position":1,"cik":"0002093620","reported_name":"Farag Kameel D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2026-08-19T21:00:01.000Z","date":"2026-08-17","kind":"grant","planned":false,"acquired":true,"shares":1728,"price":7.52,"value":12994.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These American Depositary Shares represent restricted stock units (\"RSUs\"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. The RSUs will vest in full on September 15, 2026."}],"balance_after":23309,"source":{"system":"sec-edgar","filing":"0001493152-26-039246","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2093620/000149315226039246/ownership.xml","form_type":"4"}},{"id":696048,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":21766,"kind":"person","name":"Farag Kameel D.","position":1,"cik":"0002093620","reported_name":"Farag Kameel D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2026-08-05T22:30:02.000Z","date":"2026-07-16","kind":"grant","planned":false,"acquired":true,"shares":1130,"price":11.5,"value":12995.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These American Depositary Shares represent restricted stock units (\"RSUs\"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. The RSUs will vest in full on August 16, 2026."}],"balance_after":21581,"source":{"system":"sec-edgar","filing":"0001493152-26-036231","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2093620/000149315226036231/ownership.xml","form_type":"4"}},{"id":706461,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant to purchase ADSs","published_at":"2026-07-17T10:03:07.000Z","date":"2026-07-07","kind":"exercise","planned":false,"acquired":true,"shares":5799,"price":16.16,"value":93711.84,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 5,799 ADSs, at a purchase price of $16.16 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) warrants to purchase up to 5,799 ADSs."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 5,799 ADSs, at a purchase price of $16.16 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) warrants to purchase up to 5,799 ADSs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The pre-funded warrants became exercisable upon shareholder approval, which was obtained on March 2, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The pre-funded warrants remain exercisable until fully exercised."}],"balance_after":0,"derivative":{"exercise_price":0.0004,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":5799},"source":{"system":"sec-edgar","filing":"0001493152-26-033634","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315226033634/ownership.xml","form_type":"4"}},{"id":706460,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant to purchase ADSs","published_at":"2026-07-17T10:03:07.000Z","date":"2026-07-07","kind":"exercise","planned":false,"acquired":true,"shares":15466,"price":16.16,"value":249930.56,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The combined purchase price per one pre-funded warrant and accompanying Series G Warrant was $16.16."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The pre-funded warrants became exercisable upon shareholder approval, which was obtained on March 2, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The pre-funded warrants remain exercisable until fully exercised."}],"balance_after":0,"derivative":{"exercise_price":0.0004,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":15466},"source":{"system":"sec-edgar","filing":"0001493152-26-033634","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315226033634/ownership.xml","form_type":"4"}},{"id":706459,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant to purchase American Depositary Shares","published_at":"2026-07-17T10:03:07.000Z","date":"2026-07-07","kind":"exercise","planned":false,"acquired":true,"shares":1209,"price":32,"value":38688.0,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 80,000 ordinary shares with a par value of $0.000000005 per ordinary share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The pre-funded warrants remain exercisable until fully exercised."}],"balance_after":0,"derivative":{"exercise_price":8,"exercise_date":"2023-10-06","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":1209},"source":{"system":"sec-edgar","filing":"0001493152-26-033634","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315226033634/ownership.xml","form_type":"4"}},{"id":706458,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2026-07-17T10:03:07.000Z","date":"2026-07-07","kind":"exercise","planned":false,"acquired":true,"shares":5799,"price":0.0004,"value":2.3196,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"balance_after":98241,"source":{"system":"sec-edgar","filing":"0001493152-26-033634","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315226033634/ownership.xml","form_type":"4"}},{"id":706457,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2026-07-17T10:03:07.000Z","date":"2026-07-07","kind":"exercise","planned":false,"acquired":true,"shares":15466,"price":0.0004,"value":6.1864,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"balance_after":92442,"source":{"system":"sec-edgar","filing":"0001493152-26-033634","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315226033634/ownership.xml","form_type":"4"}},{"id":706456,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2026-07-17T10:03:07.000Z","date":"2026-07-07","kind":"exercise","planned":false,"acquired":true,"shares":1209,"price":8,"value":9672.0,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"balance_after":76976,"source":{"system":"sec-edgar","filing":"0001493152-26-033634","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315226033634/ownership.xml","form_type":"4"}},{"id":726723,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":21766,"kind":"person","name":"Farag Kameel D.","position":1,"cik":"0002093620","reported_name":"Farag Kameel D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2026-06-26T00:06:51.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":1000,"price":13,"value":13000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These American Depositary Shares represent restricted stock units (\"RSUs\"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. The RSUs vested in full on June 24, 2026."}],"balance_after":20452,"source":{"system":"sec-edgar","filing":"0001493152-26-030210","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2093620/000149315226030210/ownership.xml","form_type":"4"}},{"id":726722,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":21766,"kind":"person","name":"Farag Kameel D.","position":1,"cik":"0002093620","reported_name":"Farag Kameel D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2026-06-26T00:06:51.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":7353,"price":3.74,"value":27500.22,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These American Depositary Shares represent restricted stock units (\"RSUs\"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. The RSUs vested in full on June 24, 2026."}],"balance_after":19452,"source":{"system":"sec-edgar","filing":"0001493152-26-030210","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2093620/000149315226030210/ownership.xml","form_type":"4"}},{"id":726721,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":21766,"kind":"person","name":"Farag Kameel D.","position":1,"cik":"0002093620","reported_name":"Farag Kameel D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2026-06-26T00:06:51.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":3725,"price":3.49,"value":13000.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These American Depositary Shares represent restricted stock units (\"RSUs\"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. The RSUs vested in full on June 24, 2026."}],"balance_after":12099,"source":{"system":"sec-edgar","filing":"0001493152-26-030210","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2093620/000149315226030210/ownership.xml","form_type":"4"}},{"id":726720,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":21766,"kind":"person","name":"Farag Kameel D.","position":1,"cik":"0002093620","reported_name":"Farag Kameel D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2026-06-26T00:06:51.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":2539,"price":5.12,"value":12999.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These American Depositary Shares represent restricted stock units (\"RSUs\"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. The RSUs vested in full on June 24, 2026."}],"balance_after":8374,"source":{"system":"sec-edgar","filing":"0001493152-26-030210","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2093620/000149315226030210/ownership.xml","form_type":"4"}},{"id":726719,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":21766,"kind":"person","name":"Farag Kameel D.","position":1,"cik":"0002093620","reported_name":"Farag Kameel D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2026-06-26T00:06:51.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":1570,"price":8.28,"value":12999.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These American Depositary Shares represent restricted stock units (\"RSUs\"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. The RSUs vested in full on June 24, 2026."}],"balance_after":5835,"source":{"system":"sec-edgar","filing":"0001493152-26-030210","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2093620/000149315226030210/ownership.xml","form_type":"4"}},{"id":726718,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":21766,"kind":"person","name":"Farag Kameel D.","position":1,"cik":"0002093620","reported_name":"Farag Kameel D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2026-06-26T00:06:51.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":1395,"price":9.32,"value":13001.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These American Depositary Shares represent restricted stock units (\"RSUs\"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. The RSUs vested in full on June 24, 2026."}],"balance_after":4265,"source":{"system":"sec-edgar","filing":"0001493152-26-030210","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2093620/000149315226030210/ownership.xml","form_type":"4"}},{"id":726717,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":21766,"kind":"person","name":"Farag Kameel D.","position":1,"cik":"0002093620","reported_name":"Farag Kameel D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2026-06-26T00:06:51.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":1248,"price":10.02,"value":12504.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These American Depositary Shares represent restricted stock units (\"RSUs\"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. The RSUs vested in full on June 24, 2026."}],"balance_after":2870,"source":{"system":"sec-edgar","filing":"0001493152-26-030210","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2093620/000149315226030210/ownership.xml","form_type":"4"}},{"id":726704,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":35441,"kind":"person","name":"Gaslightwala Abizer","position":1,"cik":"0002049375","reported_name":"Gaslightwala Abizer","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-26T00:04:19.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":15563,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":15563,"derivative":{"exercise_price":14.63,"exercise_date":"2026-06-24","expiration_date":"2036-06-24","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":15563},"source":{"system":"sec-edgar","filing":"0001493152-26-030207","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2049375/000149315226030207/ownership.xml","form_type":"4"}},{"id":726703,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":35441,"kind":"person","name":"Gaslightwala Abizer","position":1,"cik":"0002049375","reported_name":"Gaslightwala Abizer","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-26T00:04:19.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On April 1, 2026, the reporting person was granted an option to purchase 15,000 American Depositary Shares, with each American Depositary Share representing 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. The option vests in three installments based on the closing of qualified financings of at least $15,000,000 in gross proceeds on or before June 30, 2026. The Issuer closed a qualified financing of $5,500,000, resulting in the vesting of the option as to 5,500 American Depositary Shares."}],"balance_after":5500,"derivative":{"exercise_price":4.64,"exercise_date":"2026-06-24","expiration_date":"2036-04-01","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001493152-26-030207","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2049375/000149315226030207/ownership.xml","form_type":"4"}},{"id":841229,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":28198,"kind":"person","name":"Neal James R","position":1,"cik":"0001600865","reported_name":"Neal James R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants to purchase ADRs","published_at":"2026-03-16T21:00:03.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":3093,"price":0.4041,"value":1249.8813,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 3,093 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 3,219 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Conversion Exercise Price of Security is $0.00001"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 3,093 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 3,219 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."}],"balance_after":3093,"derivative":{"exercise_price":0,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":3093},"source":{"system":"sec-edgar","filing":"0001493152-26-010304","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315226010304/ownership.xml","form_type":"4"}},{"id":841228,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":28198,"kind":"person","name":"Neal James R","position":1,"cik":"0001600865","reported_name":"Neal James R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants to purchase ADRs","published_at":"2026-03-16T21:00:03.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":3093,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 3,093 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 3,219 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 3,093 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 3,219 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."}],"balance_after":3093,"derivative":{"exercise_price":0.3883,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":3093},"source":{"system":"sec-edgar","filing":"0001493152-26-010304","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315226010304/ownership.xml","form_type":"4"}},{"id":841227,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":28198,"kind":"person","name":"Neal James R","position":1,"cik":"0001600865","reported_name":"Neal James R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants to purchase ADRs","published_at":"2026-03-16T21:00:03.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":2473,"price":0.4041,"value":999.3393,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F2","text":"On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 2,473 ADSs (the \"PIPE PFWs\" and ) and (ii) accompanying Series G Warrants to purchase up to 2,473 ADSs (the \"Series G Warrants\"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Conversion Exercise Price of Security is $0.00001"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."}],"balance_after":2473,"derivative":{"exercise_price":0,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":2473},"source":{"system":"sec-edgar","filing":"0001493152-26-010304","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315226010304/ownership.xml","form_type":"4"}},{"id":841226,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":28198,"kind":"person","name":"Neal James R","position":1,"cik":"0001600865","reported_name":"Neal James R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants to purchase American Depositary Shares (\"ADRs\")","published_at":"2026-03-16T21:00:03.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":2473,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F2","text":"On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 2,473 ADSs (the \"PIPE PFWs\" and ) and (ii) accompanying Series G Warrants to purchase up to 2,473 ADSs (the \"Series G Warrants\"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."}],"balance_after":2473,"derivative":{"exercise_price":0.3883,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":2473},"source":{"system":"sec-edgar","filing":"0001493152-26-010304","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315226010304/ownership.xml","form_type":"4"}},{"id":962865,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":71168,"kind":"person","name":"Prudo-Chlebosz Raymond","position":1,"cik":"0001653262","reported_name":"Prudo-Chlebosz Raymond","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants to purchase ADRs","published_at":"2025-12-19T02:58:04.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":386661,"price":0.4041,"value":156249.7101,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 386,661 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 402,395 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Conversion Exercise Price of Security is $0.00001"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 386,661 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 402,395 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."}],"balance_after":386661,"derivative":{"exercise_price":0,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":386661},"source":{"system":"sec-edgar","filing":"0001493152-25-028422","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315225028422/ownership.xml","form_type":"4"}},{"id":962864,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":71168,"kind":"person","name":"Prudo-Chlebosz Raymond","position":1,"cik":"0001653262","reported_name":"Prudo-Chlebosz Raymond","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants to purchase ADRs","published_at":"2025-12-19T02:58:04.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":386661,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 386,661 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 402,395 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 386,661 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 402,395 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."}],"balance_after":386661,"derivative":{"exercise_price":0.3883,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":386661},"source":{"system":"sec-edgar","filing":"0001493152-25-028422","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315225028422/ownership.xml","form_type":"4"}},{"id":962863,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":71168,"kind":"person","name":"Prudo-Chlebosz Raymond","position":1,"cik":"0001653262","reported_name":"Prudo-Chlebosz Raymond","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants to purchase ADRs","published_at":"2025-12-19T02:58:04.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":618658,"price":0.4041,"value":249999.6978,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F2","text":"On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 618,658 ADSs (the \"PIPE PFWs\" and ) and (ii) accompanying Series G Warrants to purchase up to 618,658 ADSs (the \"Series G Warrants\"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Conversion Exercise Price of Security is $0.00001"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."}],"balance_after":618658,"derivative":{"exercise_price":0,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":618658},"source":{"system":"sec-edgar","filing":"0001493152-25-028422","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315225028422/ownership.xml","form_type":"4"}},{"id":962862,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":71168,"kind":"person","name":"Prudo-Chlebosz Raymond","position":1,"cik":"0001653262","reported_name":"Prudo-Chlebosz Raymond","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants to purchase American Depositary Shares (\"ADRs\")","published_at":"2025-12-19T02:58:04.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":618658,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F2","text":"On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 618,658 ADSs (the \"PIPE PFWs\" and ) and (ii) accompanying Series G Warrants to purchase up to 618,658 ADSs (the \"Series G Warrants\"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."}],"balance_after":618658,"derivative":{"exercise_price":0.3883,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":618658},"source":{"system":"sec-edgar","filing":"0001493152-25-028422","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315225028422/ownership.xml","form_type":"4"}},{"id":963728,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants to purchase ADRs","published_at":"2025-12-19T02:57:24.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":154664,"price":0.4041,"value":62499.7224,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 154,664 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 160,958 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Conversion Exercise Price of Security is $0.00001"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 154,664 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 160,958 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."}],"balance_after":154664,"derivative":{"exercise_price":0,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":154664},"source":{"system":"sec-edgar","filing":"0001493152-25-028421","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000149315225028421/ownership.xml","form_type":"4"}},{"id":963727,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants to purchase ADRs","published_at":"2025-12-19T02:57:24.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":154664,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 154,664 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 160,958 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 154,664 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 160,958 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."}],"balance_after":154664,"derivative":{"exercise_price":0.3883,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":154664},"source":{"system":"sec-edgar","filing":"0001493152-25-028421","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000149315225028421/ownership.xml","form_type":"4"}},{"id":963726,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants to purchase ADRs","published_at":"2025-12-19T02:57:24.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":247462,"price":0.4041,"value":99999.3942,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F2","text":"On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 247,462 ADSs (the \"PIPE PFWs\" and ) and (ii) accompanying Series G Warrants to purchase up to 247,462 ADSs (the \"Series G Warrants\"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Conversion Exercise Price of Security is $0.00001"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."}],"balance_after":247462,"derivative":{"exercise_price":0,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":247462},"source":{"system":"sec-edgar","filing":"0001493152-25-028421","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000149315225028421/ownership.xml","form_type":"4"}},{"id":963725,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants to purchase American Depositary Shares (\"ADRs\")","published_at":"2025-12-19T02:57:24.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":247462,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F2","text":"On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 247,462 ADSs (the \"PIPE PFWs\" and ) and (ii) accompanying Series G Warrants to purchase up to 247,462 ADSs (the \"Series G Warrants\"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."}],"balance_after":247462,"derivative":{"exercise_price":0.3883,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":247462},"source":{"system":"sec-edgar","filing":"0001493152-25-028421","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000149315225028421/ownership.xml","form_type":"4"}},{"id":963428,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":21766,"kind":"person","name":"Farag Kameel D.","position":1,"cik":"0002093620","reported_name":"Farag Kameel D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"Pre-Funded Warrants to purchase ADRs","published_at":"2025-12-19T02:57:09.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":24745,"price":0.4041,"value":9999.4545,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F2","text":"On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 24,745 ADSs (the \"PIPE PFWs\" and ) and (ii) accompanying Series G Warrants to purchase up to 24,745 ADSs (the \"Series G Warrants\"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Conversion Exercise Price of Security is $0.00001"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the Private Placement Unregistered Warrants remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the Private Placement Unregistered Warrants remaining exercisable until fully exercised."}],"balance_after":24745,"derivative":{"exercise_price":0,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":24745},"source":{"system":"sec-edgar","filing":"0001493152-25-028419","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2093620/000149315225028419/ownership.xml","form_type":"4"}},{"id":963427,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":21766,"kind":"person","name":"Farag Kameel D.","position":1,"cik":"0002093620","reported_name":"Farag Kameel D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"Warrants to purchase American Depositary Shares (\"ADRs\")","published_at":"2025-12-19T02:57:09.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":24745,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F2","text":"On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 24,745 ADSs (the \"PIPE PFWs\" and ) and (ii) accompanying Series G Warrants to purchase up to 24,745 ADSs (the \"Series G Warrants\"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the Private Placement Unregistered Warrants remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the Private Placement Unregistered Warrants remaining exercisable until fully exercised."}],"balance_after":24745,"derivative":{"exercise_price":0.3883,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":24745},"source":{"system":"sec-edgar","filing":"0001493152-25-028419","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2093620/000149315225028419/ownership.xml","form_type":"4"}},{"id":962861,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants to purchase ADRs","published_at":"2025-12-19T02:56:47.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":231997,"price":0.4041,"value":93749.9877,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 231,997 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 241,437 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Conversion Exercise Price of Security is $0.00001"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 231,997 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 241,437 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."}],"balance_after":231997,"derivative":{"exercise_price":0,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":231997},"source":{"system":"sec-edgar","filing":"0001493152-25-028418","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315225028418/ownership.xml","form_type":"4"}},{"id":962860,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to purchase ADRs","published_at":"2025-12-19T02:56:47.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":231997,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 231,997 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 241,437 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 231,997 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 241,437 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."}],"balance_after":231997,"derivative":{"exercise_price":0.3883,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":231997},"source":{"system":"sec-edgar","filing":"0001493152-25-028418","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315225028418/ownership.xml","form_type":"4"}},{"id":962859,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants to purchase ADRs","published_at":"2025-12-19T02:56:47.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":618658,"price":0.4041,"value":249999.6978,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F2","text":"On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 618,658 ADSs (the \"PIPE PFWs\" and ) and (ii) accompanying Series G Warrants to purchase up to 618,658 ADSs (the \"Series G Warrants\"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Conversion Exercise Price of Security is $0.00001"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."}],"balance_after":618658,"derivative":{"exercise_price":0,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":618658},"source":{"system":"sec-edgar","filing":"0001493152-25-028418","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315225028418/ownership.xml","form_type":"4"}},{"id":962858,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to purchase American Depositary Shares (\"ADRs\")","published_at":"2025-12-19T02:56:47.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":618658,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F2","text":"On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 618,658 ADSs (the \"PIPE PFWs\" and ) and (ii) accompanying Series G Warrants to purchase up to 618,658 ADSs (the \"Series G Warrants\"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."}],"balance_after":618658,"derivative":{"exercise_price":0.3883,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":618658},"source":{"system":"sec-edgar","filing":"0001493152-25-028418","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315225028418/ownership.xml","form_type":"4"}},{"id":963404,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":35441,"kind":"person","name":"Gaslightwala Abizer","position":1,"cik":"0002049375","reported_name":"Gaslightwala Abizer","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Pre-Funded Warrants to purchase ADRs","published_at":"2025-12-19T02:56:14.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":773323,"price":0.4041,"value":312499.8243,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 773,323 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 804,790 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Conversion Exercise Price of Security is $0.00001"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 773,323 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 804,790 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."}],"balance_after":773323,"derivative":{"exercise_price":0,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":773323},"source":{"system":"sec-edgar","filing":"0001493152-25-028417","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2049375/000149315225028417/ownership.xml","form_type":"4"}},{"id":963403,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":35441,"kind":"person","name":"Gaslightwala Abizer","position":1,"cik":"0002049375","reported_name":"Gaslightwala Abizer","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Warrants to purchase ADRs","published_at":"2025-12-19T02:56:14.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":773323,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 773,323 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 804,790 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 773,323 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 804,790 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."}],"balance_after":773323,"derivative":{"exercise_price":0.3883,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":773323},"source":{"system":"sec-edgar","filing":"0001493152-25-028417","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2049375/000149315225028417/ownership.xml","form_type":"4"}},{"id":963402,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":35441,"kind":"person","name":"Gaslightwala Abizer","position":1,"cik":"0002049375","reported_name":"Gaslightwala Abizer","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Pre-Funded Warrants to purchase ADRs","published_at":"2025-12-19T02:56:14.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":309328,"price":0.4041,"value":124999.4448,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F2","text":"On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 309,328 ADSs (the \"PIPE PFWs\" and ) and (ii) accompanying Series G Warrants to purchase up to 309,328 ADSs (the \"Series G Warrants\"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Conversion Exercise Price of Security is $0.00001"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series G Warrants and the PIPE PFW shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series G Warrants and the PIPE PFW shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."}],"balance_after":309328,"derivative":{"exercise_price":0,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":309328},"source":{"system":"sec-edgar","filing":"0001493152-25-028417","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2049375/000149315225028417/ownership.xml","form_type":"4"}},{"id":963401,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":35441,"kind":"person","name":"Gaslightwala Abizer","position":1,"cik":"0002049375","reported_name":"Gaslightwala Abizer","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Warrants to purchase American Depositary Shares (\"ADRs\")","published_at":"2025-12-19T02:56:14.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":309328,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F2","text":"On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 309,328 ADSs (the \"PIPE PFWs\" and ) and (ii) accompanying Series G Warrants to purchase up to 309,328 ADSs (the \"Series G Warrants\"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series G Warrants and the PIPE PFW shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series G Warrants and the PIPE PFW shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."}],"balance_after":309328,"derivative":{"exercise_price":0.3883,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":309328},"source":{"system":"sec-edgar","filing":"0001493152-25-028417","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2049375/000149315225028417/ownership.xml","form_type":"4"}},{"id":962855,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants to purchase ADRs","published_at":"2025-12-19T02:56:12.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":30932,"price":0.4041,"value":12499.6212,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 30,932 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 32,191 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Conversion Exercise Price of Security is $0.00001"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 30,932 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 32,191 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."}],"balance_after":30932,"derivative":{"exercise_price":0,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":30932},"source":{"system":"sec-edgar","filing":"0001493152-25-028416","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315225028416/ownership.xml","form_type":"4"}},{"id":962854,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants to purchase ADRs","published_at":"2025-12-19T02:56:12.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":30932,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 30,932 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 32,191 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 30,932 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 32,191 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."}],"balance_after":30932,"derivative":{"exercise_price":0.3883,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":30932},"source":{"system":"sec-edgar","filing":"0001493152-25-028416","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315225028416/ownership.xml","form_type":"4"}},{"id":962853,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants to purchase ADRs","published_at":"2025-12-19T02:56:12.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":123731,"price":0.4041,"value":49999.6971,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F2","text":"On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 123,731 ADSs (the \"PIPE PFWs\" and ) and (ii) accompanying Series G Warrants to purchase up to 123,731 ADSs (the \"Series G Warrants\"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Conversion Exercise Price of Security is $0.00001"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."}],"balance_after":123731,"derivative":{"exercise_price":0,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":123731},"source":{"system":"sec-edgar","filing":"0001493152-25-028416","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315225028416/ownership.xml","form_type":"4"}},{"id":962852,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants to purchase American Depositary Shares (\"ADRs\")","published_at":"2025-12-19T02:56:12.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":123731,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F2","text":"On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 123,731 ADSs (the \"PIPE PFWs\" and ) and (ii) accompanying Series G Warrants to purchase up to 123,731 ADSs (the \"Series G Warrants\"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."}],"balance_after":123731,"derivative":{"exercise_price":0.3883,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":123731},"source":{"system":"sec-edgar","filing":"0001493152-25-028416","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315225028416/ownership.xml","form_type":"4"}},{"id":963054,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants to purchase ADRs","published_at":"2025-12-18T21:57:12.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":3093293,"price":0.4041,"value":1249999.7013,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 3,093,293 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 3,219,160 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Conversion Exercise Price of Security is $0.00001"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 3,093,293 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 3,219,160 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."}],"balance_after":3093293,"derivative":{"exercise_price":0,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":3093293},"source":{"system":"sec-edgar","filing":"0001493152-25-028420","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000149315225028420/ownership.xml","form_type":"4"}},{"id":963053,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to purchase ADRs","published_at":"2025-12-18T21:57:12.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":3093293,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 3,093,293 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 3,219,160 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 3,093,293 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 3,219,160 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."}],"balance_after":3093293,"derivative":{"exercise_price":0.3883,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":3093293},"source":{"system":"sec-edgar","filing":"0001493152-25-028420","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000149315225028420/ownership.xml","form_type":"4"}},{"id":963052,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants to purchase ADRs","published_at":"2025-12-18T21:57:12.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":618658,"price":0.4041,"value":249999.6978,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F2","text":"On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 618,658 ADSs (the \"PIPE PFWs\" and ) and (ii) accompanying Series G Warrants to purchase up to 618,658 ADSs (the \"Series G Warrants\"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Conversion Exercise Price of Security is $0.00001"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."}],"balance_after":618658,"derivative":{"exercise_price":0,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":618658},"source":{"system":"sec-edgar","filing":"0001493152-25-028420","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000149315225028420/ownership.xml","form_type":"4"}},{"id":963051,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to purchase American Depositary Shares (\"ADRs\")","published_at":"2025-12-18T21:57:12.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":618658,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F2","text":"On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 618,658 ADSs (the \"PIPE PFWs\" and ) and (ii) accompanying Series G Warrants to purchase up to 618,658 ADSs (the \"Series G Warrants\"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."}],"balance_after":618658,"derivative":{"exercise_price":0.3883,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":618658},"source":{"system":"sec-edgar","filing":"0001493152-25-028420","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000149315225028420/ownership.xml","form_type":"4"}},{"id":1008456,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":21766,"kind":"person","name":"Farag Kameel D.","position":1,"cik":"0002093620","reported_name":"Farag Kameel D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-11-04T22:00:02.000Z","date":"2025-11-01","kind":"grant","planned":false,"acquired":true,"shares":26619,"price":0.75,"value":19964.25,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer"},{"field":"shares","element":"transactionShares","label":"F3","text":"These ADSs represent restricted stock units (\"RSUs\"), with each such RSU representing the right to receive 2,000 Ordinary Shares par value $0.0001. The RSUs shall vest on February 15, 2026."}],"balance_after":26619,"source":{"system":"sec-edgar","filing":"0001493152-25-020753","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2093620/000149315225020753/ownership.xml","form_type":"4"}},{"id":1008455,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":21766,"kind":"person","name":"Farag Kameel D.","position":1,"cik":"0002093620","reported_name":"Farag Kameel D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-11-04T22:00:02.000Z","date":"2025-11-01","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0.75,"value":24000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer"},{"field":"shares","element":"transactionShares","label":"F2","text":"These ADSs represent restricted stock units (\"RSUs\"), with each such RSU representing the right to receive 2,000 Ordinary Shares par value $0.0001. The RSUs shall vest on January 1, 2026."}],"balance_after":32000,"source":{"system":"sec-edgar","filing":"0001493152-25-020753","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2093620/000149315225020753/ownership.xml","form_type":"4"}},{"id":1013911,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":21766,"kind":"person","name":"Farag Kameel D.","position":1,"cik":"0002093620","reported_name":"Farag Kameel D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-10-24T13:18:57.000Z","date":"2025-10-22","kind":"grant","planned":false,"acquired":true,"shares":6277,"price":0.74,"value":4644.98,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer"},{"field":"shares","element":"transactionShares","label":"F2","text":"These ADSs represent restricted stock units (\"RSUs\"), with each such RSU representing the right to receive 2,000 Ordinary Shares par value $0.0001. The RSUs shall vest on October 31, 2025."}],"balance_after":6277,"source":{"system":"sec-edgar","filing":"0001493152-25-019194","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2093620/000149315225019194/ownership.xml","form_type":"4"}},{"id":1053042,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":35441,"kind":"person","name":"Gaslightwala Abizer","position":1,"cik":"0002049375","reported_name":"Gaslightwala Abizer","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-08-29T20:55:12.000Z","date":"2025-08-25","kind":"purchase","planned":false,"acquired":true,"shares":3000,"price":0.9,"value":2700.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.89 to $0.90, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within ranges set forth in this footnote."}],"balance_after":298574,"source":{"system":"sec-edgar","filing":"0001641172-25-026025","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2049375/000164117225026025/ownership.xml","form_type":"4"}},{"id":1053041,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":35441,"kind":"person","name":"Gaslightwala Abizer","position":1,"cik":"0002049375","reported_name":"Gaslightwala Abizer","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-08-29T20:55:12.000Z","date":"2025-08-22","kind":"purchase","planned":false,"acquired":true,"shares":8000,"price":0.93,"value":7440.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.92 to $0.93, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within ranges set forth in this footnote."}],"balance_after":295574,"source":{"system":"sec-edgar","filing":"0001641172-25-026025","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2049375/000164117225026025/ownership.xml","form_type":"4"}},{"id":1053040,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":35441,"kind":"person","name":"Gaslightwala Abizer","position":1,"cik":"0002049375","reported_name":"Gaslightwala Abizer","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-08-29T20:55:12.000Z","date":"2025-08-21","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":0.94,"value":9400.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.93 to $0.94, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within ranges set forth in this footnote."}],"balance_after":287574,"source":{"system":"sec-edgar","filing":"0001641172-25-026025","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2049375/000164117225026025/ownership.xml","form_type":"4"}},{"id":1101862,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":35441,"kind":"person","name":"Gaslightwala Abizer","position":1,"cik":"0002049375","reported_name":"Gaslightwala Abizer","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-06-25T20:30:04.000Z","date":"2025-06-24","kind":"purchase","planned":false,"acquired":true,"shares":5203,"price":1.16,"value":6035.48,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.15 to $1.16, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within ranges set forth in this footnote."}],"balance_after":277574,"source":{"system":"sec-edgar","filing":"0000950170-25-089976","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2049375/000095017025089976/ownership.xml","form_type":"4"}},{"id":1101861,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":35441,"kind":"person","name":"Gaslightwala Abizer","position":1,"cik":"0002049375","reported_name":"Gaslightwala Abizer","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-06-25T20:30:04.000Z","date":"2025-06-23","kind":"purchase","planned":false,"acquired":true,"shares":943,"price":1.15,"value":1084.45,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":272371,"source":{"system":"sec-edgar","filing":"0000950170-25-089976","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2049375/000095017025089976/ownership.xml","form_type":"4"}},{"id":1102861,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":35441,"kind":"person","name":"Gaslightwala Abizer","position":1,"cik":"0002049375","reported_name":"Gaslightwala Abizer","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-06-24T20:30:10.000Z","date":"2025-06-20","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":1.2,"value":12000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":271428,"source":{"system":"sec-edgar","filing":"0000950170-25-089462","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2049375/000095017025089462/ownership.xml","form_type":"4"}},{"id":1105246,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":35441,"kind":"person","name":"Gaslightwala Abizer","position":1,"cik":"0002049375","reported_name":"Gaslightwala Abizer","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-06-20T20:05:04.000Z","date":"2025-06-17","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":1.2,"value":18000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":261428,"source":{"system":"sec-edgar","filing":"0000950170-25-088490","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2049375/000095017025088490/ownership.xml","form_type":"4"}},{"id":1110110,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":35441,"kind":"person","name":"Gaslightwala Abizer","position":1,"cik":"0002049375","reported_name":"Gaslightwala Abizer","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-06-16T21:00:17.000Z","date":"2025-06-13","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":1.19,"value":29750.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On June 13, 2025, the Reporting Person acquired 10,000 ADS at an average price of $1.19 per ADS."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On June 13, 2025, the Reporting Person acquired 10,000 ADS at an average price of $1.19 per ADS."}],"balance_after":246428,"source":{"system":"sec-edgar","filing":"0000950170-25-086829","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2049375/000095017025086829/ownership.xml","form_type":"4"}},{"id":1110109,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":35441,"kind":"person","name":"Gaslightwala Abizer","position":1,"cik":"0002049375","reported_name":"Gaslightwala Abizer","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-06-16T21:00:17.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":1.23,"value":24600.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 12, 2025, the Reporting Person acquired 20,000 ADS at an average price of $1.23 per ADS."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 12, 2025, the Reporting Person acquired 20,000 ADS at an average price of $1.23 per ADS."}],"balance_after":221428,"source":{"system":"sec-edgar","filing":"0000950170-25-086829","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2049375/000095017025086829/ownership.xml","form_type":"4"}},{"id":1113841,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":35441,"kind":"person","name":"Gaslightwala Abizer","position":1,"cik":"0002049375","reported_name":"Gaslightwala Abizer","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-06-12T20:30:29.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":1.27,"value":25400.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 10, 2025, the Reporting Person acquired 20,000 ADS at an average price of $1.27 per ADS."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 10, 2025, the Reporting Person acquired 20,000 ADS at an average price of $1.27 per ADS."}],"balance_after":201428,"source":{"system":"sec-edgar","filing":"0000950170-25-085472","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2049375/000095017025085472/ownership.xml","form_type":"4"}},{"id":1164432,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Warrants (Right to Buy)","published_at":"2025-04-29T21:00:12.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":44642,"price":1.12,"value":49999.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On April 25, 2025, the Reporting Person acquired 44,642 ADS  and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On April 25, 2025, the Reporting Person acquired 44,642 ADS  and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":44642,"derivative":{"exercise_price":0.87,"exercise_date":"2025-03-06","expiration_date":"2030-03-06","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":44642},"source":{"system":"sec-edgar","filing":"0000950170-25-060298","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000095017025060298/ownership.xml","form_type":"4"}},{"id":1164431,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Warrants (Right to Buy)","published_at":"2025-04-29T21:00:12.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":44642,"price":1.12,"value":49999.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On April 25, 2025, the Reporting Person acquired 44,642 ADS  and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On April 25, 2025, the Reporting Person acquired 44,642 ADS  and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":44642,"derivative":{"exercise_price":0.87,"exercise_date":"2025-03-06","expiration_date":"2026-03-06","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":44642},"source":{"system":"sec-edgar","filing":"0000950170-25-060298","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000095017025060298/ownership.xml","form_type":"4"}},{"id":1164430,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-04-29T21:00:12.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":44642,"price":1.12,"value":49999.04,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On April 25, 2025, the Reporting Person acquired 44,642 ADS  and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On April 25, 2025, the Reporting Person acquired 44,642 ADS  and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."}],"balance_after":496499,"source":{"system":"sec-edgar","filing":"0000950170-25-060298","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000095017025060298/ownership.xml","form_type":"4"}},{"id":1193162,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":28198,"kind":"person","name":"Neal James R","position":1,"cik":"0001600865","reported_name":"Neal James R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-24T21:00:16.000Z","date":"2025-03-20","kind":"grant","planned":false,"acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. Subject to the Reporting Person's continued service with the Issuer and shareholder approval covering the issuance of the ADS underlying this stock option, this option shall vest (i) 25% on the grant date (ii) 25% on December 31, 2025 and (iii) the remaining 50% shall vest ratably on a monthly basis over the 24 month period thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":225000,"derivative":{"exercise_price":1.5,"expiration_date":"2035-03-20","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0000950170-25-043940","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025043940/ownership.xml","form_type":"4"}},{"id":1193161,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":28198,"kind":"person","name":"Neal James R","position":1,"cik":"0001600865","reported_name":"Neal James R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-24T21:00:16.000Z","date":"2025-03-20","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock option shall vest over four years from the grant date with 25% vesting on the 12 month anniversary of the grant date, and the remainder vesting ratably on a monthly basis over the then remaining 36 months from the grant date, such that it will be fully vested on the fourth anniversary of the grant date. The stock option award is subject to continued service with the Issuer."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":175000,"derivative":{"exercise_price":1.5,"expiration_date":"2035-03-20","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0000950170-25-043940","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025043940/ownership.xml","form_type":"4"}},{"id":1193160,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-24T21:00:15.000Z","date":"2025-03-20","kind":"grant","planned":false,"acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. Subject to the Reporting Person's continued service with the Issuer and shareholder approval covering the issuance of the ADS underlying this stock option, this option shall vest (i) 25% on the grant date (ii) 25% on December 31, 2025 and (iii) the remaining 50% shall vest ratably on a monthly basis over the 24 month period thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":225000,"derivative":{"exercise_price":1.5,"expiration_date":"2035-03-20","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0000950170-25-043939","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025043939/ownership.xml","form_type":"4"}},{"id":1193159,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-24T21:00:15.000Z","date":"2025-03-20","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock option shall vest over four years from the grant date with 25% vesting on the 12 month anniversary of the grant date, and the remainder vesting ratably on a monthly basis over the then remaining 36 months from the grant date, such that it will be fully vested on the fourth anniversary of the grant date. The stock option award is subject to continued service with the Issuer."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":175000,"derivative":{"exercise_price":1.5,"expiration_date":"2035-03-20","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0000950170-25-043939","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025043939/ownership.xml","form_type":"4"}},{"id":1193158,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-24T21:00:13.000Z","date":"2025-03-20","kind":"grant","planned":false,"acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. Subject to the Reporting Person's continued service with the Issuer and shareholder approval covering the issuance of the ADS underlying this stock option, this option shall vest (i) 25% on the grant date (ii) 25% on December 31, 2025 and (iii) the remaining 50% shall vest ratably on a monthly basis over the 24 month period thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":225000,"derivative":{"exercise_price":1.5,"expiration_date":"2035-03-20","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0000950170-25-043938","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025043938/ownership.xml","form_type":"4"}},{"id":1193157,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-24T21:00:13.000Z","date":"2025-03-20","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock option shall vest over four years from the grant date with 25% vesting on the 12 month anniversary of the grant date, and the remainder vesting ratably on a monthly basis over the then remaining 36 months from the grant date, such that it will be fully vested on the fourth anniversary of the grant date. The stock option award is subject to continued service with the Issuer."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":175000,"derivative":{"exercise_price":1.5,"expiration_date":"2035-03-20","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0000950170-25-043938","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025043938/ownership.xml","form_type":"4"}},{"id":1194120,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-24T21:00:12.000Z","date":"2025-03-20","kind":"grant","planned":false,"acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. Subject to the Reporting Person's continued service with the Issuer and shareholder approval covering the issuance of the ADS underlying this stock option, this option shall vest (i) 25% on the grant date (ii) 25% on December 31, 2025 and (iii) the remaining 50% shall vest ratably on a monthly basis over the 24 month period thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":225000,"derivative":{"exercise_price":1.5,"expiration_date":"2035-03-20","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0000950170-25-043935","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000095017025043935/ownership.xml","form_type":"4"}},{"id":1194119,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":30204,"kind":"person","name":"Patel Sandip I","position":1,"cik":"0001843601","reported_name":"Patel Sandip I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-24T21:00:12.000Z","date":"2025-03-20","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock option shall vest over four years from the grant date with 25% vesting on the 12 month anniversary of the grant date, and the remainder vesting ratably on a monthly basis over the then remaining 36 months from the grant date, such that it will be fully vested on the fourth anniversary of the grant date. The stock option award is subject to continued service with the Issuer."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":175000,"derivative":{"exercise_price":1.5,"expiration_date":"2035-03-20","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0000950170-25-043935","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1843601/000095017025043935/ownership.xml","form_type":"4"}},{"id":1193156,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":71168,"kind":"person","name":"Prudo-Chlebosz Raymond","position":1,"cik":"0001653262","reported_name":"Prudo-Chlebosz Raymond","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-24T21:00:11.000Z","date":"2025-03-20","kind":"grant","planned":false,"acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. Subject to the Reporting Person's continued service with the Issuer and shareholder approval covering the issuance of the ADS underlying this stock option, this option shall vest (i) 25% on the grant date (ii) 25% on December 31, 2025 and (iii) the remaining 50% shall vest ratably on a monthly basis over the 24 month period thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":225000,"derivative":{"exercise_price":1.5,"expiration_date":"2035-03-20","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0000950170-25-043937","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025043937/ownership.xml","form_type":"4"}},{"id":1193155,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":71168,"kind":"person","name":"Prudo-Chlebosz Raymond","position":1,"cik":"0001653262","reported_name":"Prudo-Chlebosz Raymond","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-24T21:00:11.000Z","date":"2025-03-20","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock option shall vest over four years from the grant date with 25% vesting on the 12 month anniversary of the grant date, and the remainder vesting ratably on a monthly basis over the then remaining 36 months from the grant date, such that it will be fully vested on the fourth anniversary of the grant date. The stock option award is subject to continued service with the Issuer."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":175000,"derivative":{"exercise_price":1.5,"expiration_date":"2035-03-20","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0000950170-25-043937","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025043937/ownership.xml","form_type":"4"}},{"id":1193151,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":81618,"kind":"person","name":"Hombeck Torsten","position":1,"cik":"0001983682","reported_name":"Hombeck Torsten","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-24T21:00:10.000Z","date":"2025-03-20","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock options shall vest upon achievement of at least one of the following performance criteria: either (a) closing of a qualified financing of at least $15,000,000 in gross proceeds on or before December 31, 2025, or (b) closing of an antibody drug conjugate (\"ADC\") focused license transaction, with a minimum upfront payment of $10,000,000 on or before December 31, 2025. If neither of these criteria are met by December 31, 2025 the performance-based option will expire. The stock option award is subject to continued service with the Issuer."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":200000,"derivative":{"exercise_price":1.5,"expiration_date":"2035-03-20","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000950170-25-043934","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025043934/ownership.xml","form_type":"4"}},{"id":1193150,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":81618,"kind":"person","name":"Hombeck Torsten","position":1,"cik":"0001983682","reported_name":"Hombeck Torsten","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-24T21:00:10.000Z","date":"2025-03-20","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock option shall vest over four years from the grant date with 25% vesting on the 12 month anniversary of the grant date, and the remainder vesting ratably on a monthly basis over the then remaining 36 months from the grant date, such that it will be fully vested on the fourth anniversary of the grant date. The stock option award is subject to continued service with the Issuer."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":300000,"derivative":{"exercise_price":1.5,"expiration_date":"2035-03-20","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0000950170-25-043934","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025043934/ownership.xml","form_type":"4"}},{"id":1193778,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":35441,"kind":"person","name":"Gaslightwala Abizer","position":1,"cik":"0002049375","reported_name":"Gaslightwala Abizer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-24T21:00:08.000Z","date":"2025-03-20","kind":"grant","planned":false,"acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock options shall vest upon achievement of at least one of the following performance criteria: either (a) closing of a qualified financing of at least $15,000,000 in gross proceeds on or before December 31, 2025, or (b) closing of an antibody drug conjugate (\"ADC\") focused license transaction, with a minimum upfront payment of $10,000,000 on or before December 31, 2025. If neither of these criteria are met by December 31, 2025 the performance-based option will expire. The stock option award is subject to continued service with the Issuer."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":600000,"derivative":{"exercise_price":1.5,"expiration_date":"2035-03-20","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0000950170-25-043933","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2049375/000095017025043933/ownership.xml","form_type":"4"}},{"id":1193777,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":35441,"kind":"person","name":"Gaslightwala Abizer","position":1,"cik":"0002049375","reported_name":"Gaslightwala Abizer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-24T21:00:08.000Z","date":"2025-03-20","kind":"grant","planned":false,"acquired":true,"shares":1100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock option shall vest over four years from the grant date with 25% vesting on the 12 month anniversary of the grant date, and the remainder vesting ratably on a monthly basis over the then remaining 36 months from the grant date, such that it will be fully vested on the fourth anniversary of the grant date. The stock option award is subject to continued service with the Issuer."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":1100000,"derivative":{"exercise_price":1.5,"expiration_date":"2035-03-20","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":1100000},"source":{"system":"sec-edgar","filing":"0000950170-25-043933","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2049375/000095017025043933/ownership.xml","form_type":"4"}},{"id":1193309,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-24T17:00:10.000Z","date":"2025-03-20","kind":"grant","planned":false,"acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. Subject to the Reporting Person's continued service with the Issuer and shareholder approval covering the issuance of the ADS underlying this stock option, this option shall vest (i) 25% on the grant date (ii) 25% on December 31, 2025 and (iii) the remaining 50% shall vest ratably on a monthly basis over the 24 month period thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":225000,"derivative":{"exercise_price":1.5,"expiration_date":"2035-03-20","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0000950170-25-043936","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017025043936/ownership.xml","form_type":"4"}},{"id":1193308,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-24T17:00:10.000Z","date":"2025-03-20","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock option shall vest over four years from the grant date with 25% vesting on the 12 month anniversary of the grant date, and the remainder vesting ratably on a monthly basis over the then remaining 36 months from the grant date, such that it will be fully vested on the fourth anniversary of the grant date. The stock option award is subject to continued service with the Issuer."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":175000,"derivative":{"exercise_price":1.5,"expiration_date":"2035-03-20","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0000950170-25-043936","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017025043936/ownership.xml","form_type":"4"}},{"id":1214572,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":71168,"kind":"person","name":"Prudo-Chlebosz Raymond","position":1,"cik":"0001653262","reported_name":"Prudo-Chlebosz Raymond","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Warrants (Right to Buy)","published_at":"2025-03-10T21:00:12.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":446428,"price":1.12,"value":499999.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 446,428 ADS  and accompanying Series A and Series B warrants to purchase up to 892,856 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 446,428 ADS  and accompanying Series A and Series B warrants to purchase up to 892,856 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":446428,"derivative":{"exercise_price":0.87,"exercise_date":"2025-03-06","expiration_date":"2030-03-06","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":446428},"source":{"system":"sec-edgar","filing":"0000950170-25-036487","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025036487/ownership.xml","form_type":"4"}},{"id":1214571,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":71168,"kind":"person","name":"Prudo-Chlebosz Raymond","position":1,"cik":"0001653262","reported_name":"Prudo-Chlebosz Raymond","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Warrants (Right to Buy)","published_at":"2025-03-10T21:00:12.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":446428,"price":1.12,"value":499999.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 446,428 ADS  and accompanying Series A and Series B warrants to purchase up to 892,856 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 446,428 ADS  and accompanying Series A and Series B warrants to purchase up to 892,856 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":446428,"derivative":{"exercise_price":0.87,"exercise_date":"2025-03-06","expiration_date":"2026-03-06","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":446428},"source":{"system":"sec-edgar","filing":"0000950170-25-036487","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025036487/ownership.xml","form_type":"4"}},{"id":1214570,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":71168,"kind":"person","name":"Prudo-Chlebosz Raymond","position":1,"cik":"0001653262","reported_name":"Prudo-Chlebosz Raymond","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-03-10T21:00:12.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":446428,"price":1.12,"value":499999.36,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 446,428 ADS  and accompanying Series A and Series B warrants to purchase up to 892,856 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 446,428 ADS  and accompanying Series A and Series B warrants to purchase up to 892,856 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."}],"balance_after":2484990,"source":{"system":"sec-edgar","filing":"0000950170-25-036487","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025036487/ownership.xml","form_type":"4"}},{"id":1214569,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Warrants (Right to Buy)","published_at":"2025-03-10T21:00:10.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":406250,"price":1.12,"value":455000.0,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 406,250 ADS  and accompanying Series A and Series B warrants to purchase up to 812,500 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 406,250 ADS  and accompanying Series A and Series B warrants to purchase up to 812,500 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depository Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":406250,"derivative":{"exercise_price":0.87,"exercise_date":"2025-03-06","expiration_date":"2030-03-06","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":406250},"source":{"system":"sec-edgar","filing":"0000950170-25-036486","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025036486/ownership.xml","form_type":"4"}},{"id":1214568,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Warrants (Right to Buy)","published_at":"2025-03-10T21:00:10.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":406250,"price":1.12,"value":455000.0,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 406,250 ADS  and accompanying Series A and Series B warrants to purchase up to 812,500 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 406,250 ADS  and accompanying Series A and Series B warrants to purchase up to 812,500 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depository Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":406250,"derivative":{"exercise_price":0.87,"exercise_date":"2025-03-06","expiration_date":"2026-03-06","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":406250},"source":{"system":"sec-edgar","filing":"0000950170-25-036486","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025036486/ownership.xml","form_type":"4"}},{"id":1214567,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-03-10T21:00:10.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":406250,"price":1.12,"value":455000.0,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depository Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 406,250 ADS  and accompanying Series A and Series B warrants to purchase up to 812,500 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 406,250 ADS  and accompanying Series A and Series B warrants to purchase up to 812,500 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."}],"balance_after":3031005,"source":{"system":"sec-edgar","filing":"0000950170-25-036486","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025036486/ownership.xml","form_type":"4"}},{"id":1214566,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":28198,"kind":"person","name":"Neal James R","position":1,"cik":"0001600865","reported_name":"Neal James R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Warrants (Right to Buy)","published_at":"2025-03-10T21:00:09.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":4464,"price":1.12,"value":4999.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 4,464 ADS  and accompanying Series A and Series B warrants to purchase up to 8,928 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025.  The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 4,464 ADS  and accompanying Series A and Series B warrants to purchase up to 8,928 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025.  The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":4464,"derivative":{"exercise_price":0.87,"exercise_date":"2025-03-06","expiration_date":"2030-03-06","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":4464},"source":{"system":"sec-edgar","filing":"0000950170-25-036485","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025036485/ownership.xml","form_type":"4"}},{"id":1214565,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":28198,"kind":"person","name":"Neal James R","position":1,"cik":"0001600865","reported_name":"Neal James R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Warrants (Right to Buy)","published_at":"2025-03-10T21:00:09.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":4464,"price":1.12,"value":4999.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 4,464 ADS  and accompanying Series A and Series B warrants to purchase up to 8,928 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025.  The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 4,464 ADS  and accompanying Series A and Series B warrants to purchase up to 8,928 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025.  The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":4464,"derivative":{"exercise_price":0.87,"exercise_date":"2025-03-06","expiration_date":"2026-03-06","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":4464},"source":{"system":"sec-edgar","filing":"0000950170-25-036485","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025036485/ownership.xml","form_type":"4"}},{"id":1214564,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":28198,"kind":"person","name":"Neal James R","position":1,"cik":"0001600865","reported_name":"Neal James R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-03-10T21:00:09.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":4464,"price":1.12,"value":4999.68,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 4,464 ADS  and accompanying Series A and Series B warrants to purchase up to 8,928 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025.  The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 4,464 ADS  and accompanying Series A and Series B warrants to purchase up to 8,928 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025.  The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."}],"balance_after":36271,"source":{"system":"sec-edgar","filing":"0000950170-25-036485","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025036485/ownership.xml","form_type":"4"}},{"id":1214563,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Warrants (Right to Buy)","published_at":"2025-03-10T21:00:05.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":44642,"price":1.12,"value":49999.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 44,642 ADS  and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 44,642 ADS  and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":44642,"derivative":{"exercise_price":0.87,"exercise_date":"2025-03-06","expiration_date":"2030-03-06","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":44642},"source":{"system":"sec-edgar","filing":"0000950170-25-036482","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025036482/ownership.xml","form_type":"4"}},{"id":1214562,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Warrants (Right to Buy)","published_at":"2025-03-10T21:00:05.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":44642,"price":1.12,"value":49999.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 44,642 ADS  and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 44,642 ADS  and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":44642,"derivative":{"exercise_price":0.87,"exercise_date":"2025-03-06","expiration_date":"2026-03-06","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":44642},"source":{"system":"sec-edgar","filing":"0000950170-25-036482","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025036482/ownership.xml","form_type":"4"}},{"id":1214561,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-03-10T21:00:05.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":44642,"price":1.12,"value":49999.04,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 44,642 ADS  and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 44,642 ADS  and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."}],"balance_after":44642,"source":{"system":"sec-edgar","filing":"0000950170-25-036482","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025036482/ownership.xml","form_type":"4"}},{"id":1215524,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":35441,"kind":"person","name":"Gaslightwala Abizer","position":1,"cik":"0002049375","reported_name":"Gaslightwala Abizer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Warrants (Right to Buy)","published_at":"2025-03-10T21:00:03.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":133928,"price":1.12,"value":149999.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 133,928 ADS  and accompanying Series A and Series B warrants to purchase up to 267,856 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025.  The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 133,928 ADS  and accompanying Series A and Series B warrants to purchase up to 267,856 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025.  The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":133928,"derivative":{"exercise_price":0.87,"exercise_date":"2025-03-06","expiration_date":"2030-03-06","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":133928},"source":{"system":"sec-edgar","filing":"0000950170-25-036483","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2049375/000095017025036483/ownership.xml","form_type":"4"}},{"id":1215523,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":35441,"kind":"person","name":"Gaslightwala Abizer","position":1,"cik":"0002049375","reported_name":"Gaslightwala Abizer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Warrants (Right to Buy)","published_at":"2025-03-10T21:00:03.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":133928,"price":1.12,"value":149999.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 133,928 ADS  and accompanying Series A and Series B warrants to purchase up to 267,856 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025.  The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 133,928 ADS  and accompanying Series A and Series B warrants to purchase up to 267,856 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025.  The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":133928,"derivative":{"exercise_price":0.87,"exercise_date":"2025-03-06","expiration_date":"2026-03-06","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":133928},"source":{"system":"sec-edgar","filing":"0000950170-25-036483","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2049375/000095017025036483/ownership.xml","form_type":"4"}},{"id":1215522,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":35441,"kind":"person","name":"Gaslightwala Abizer","position":1,"cik":"0002049375","reported_name":"Gaslightwala Abizer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-03-10T21:00:03.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":133928,"price":1.12,"value":149999.36,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 133,928 ADS  and accompanying Series A and Series B warrants to purchase up to 267,856 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025.  The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 133,928 ADS  and accompanying Series A and Series B warrants to purchase up to 267,856 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025.  The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."}],"balance_after":181428,"source":{"system":"sec-edgar","filing":"0000950170-25-036483","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2049375/000095017025036483/ownership.xml","form_type":"4"}},{"id":1214894,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrants (Right to Buy)","published_at":"2025-03-10T17:00:16.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":892857,"price":1.12,"value":999999.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 892,857 ADS  and accompanying Series A and Series B warrants to purchase up to 1,785,714 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 892,857 ADS  and accompanying Series A and Series B warrants to purchase up to 1,785,714 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":892857,"derivative":{"exercise_price":0.87,"exercise_date":"2025-03-06","expiration_date":"2030-03-06","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":892857},"source":{"system":"sec-edgar","filing":"0000950170-25-036488","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017025036488/ownership.xml","form_type":"4"}},{"id":1214893,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants (Right to Buy)","published_at":"2025-03-10T17:00:16.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":892857,"price":1.12,"value":999999.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 892,857 ADS  and accompanying Series A and Series B warrants to purchase up to 1,785,714 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 892,857 ADS  and accompanying Series A and Series B warrants to purchase up to 1,785,714 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":892857,"derivative":{"exercise_price":0.87,"exercise_date":"2025-03-06","expiration_date":"2026-03-06","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":892857},"source":{"system":"sec-edgar","filing":"0000950170-25-036488","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017025036488/ownership.xml","form_type":"4"}},{"id":1214892,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-03-10T17:00:16.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":892857,"price":1.12,"value":999999.84,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 892,857 ADS  and accompanying Series A and Series B warrants to purchase up to 1,785,714 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 892,857 ADS  and accompanying Series A and Series B warrants to purchase up to 1,785,714 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."}],"balance_after":4695854,"source":{"system":"sec-edgar","filing":"0000950170-25-036488","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017025036488/ownership.xml","form_type":"4"}},{"id":1279002,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":35441,"kind":"person","name":"Gaslightwala Abizer","position":1,"cik":"0002049375","reported_name":"Gaslightwala Abizer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depository Shares representing Ordinary Shares","published_at":"2025-02-07T21:30:14.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":11640,"price":1.22,"value":14200.8,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depository Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On January 13, 2025, the Reporting Person previously reported the purchase of 11,439 ADS at purchase price of $1.22 per ADS. The Reporting Person actually acquired 11,640 ADS at a price raning from $1.22 per ADS to $1.28 per ADS. The Reporting Person also previously reported the total amount of securities beneficially owned following transaction as 35,860 and omitted the ADS acquired on January 10, 2025. The revised amount of securities beneficially owned following the transaction is 47,500 ADS."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On January 13, 2025, the Reporting Person previously reported the purchase of 11,439 ADS at purchase price of $1.22 per ADS. The Reporting Person actually acquired 11,640 ADS at a price raning from $1.22 per ADS to $1.28 per ADS. The Reporting Person also previously reported the total amount of securities beneficially owned following transaction as 35,860 and omitted the ADS acquired on January 10, 2025. The revised amount of securities beneficially owned following the transaction is 47,500 ADS."}],"balance_after":47500,"source":{"system":"sec-edgar","filing":"0000950170-25-016334","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2049375/000095017025016334/ownership.xml","form_type":"4/A","original_submission_date":"2025-01-13"}}],"next_cursor":"2025-02-07T21:30:14.000000Z,1279002"}